Cover Image

A potentially serious adverse effect of GLP-1 receptor agonists

Saved in:

Bibliographic Details
Main Authors:	Jinmiao Lu (Author), Hao Liu (Author), Qingtong Zhou (Author), Ming-Wei Wang (Author), Zhiping Li (Author)
Format:	Book
Published:	Elsevier, 2023-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
by: Long He, et al.
Published: (2024)

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
by: Jiani Zhong, et al.
Published: (2024)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022)

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists
by: Lei Sun, et al.
Published: (2022)

First vaccination after birth: serious adverse events of Bacillus Calmette-Guérin (BCG) in real-world
by: Jinmiao Lu, et al.
Published: (2022)

Inspiration to mRNA-based COVID-19 vaccination: Serious adverse case reports with hepatitis B vaccine in real-world
by: Jinmiao Lu, et al.
Published: (2022)

GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
by: Aurélie Pahud de Mortanges, et al.
Published: (2022)

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
by: Aleksandra Jaroń, et al.
Published: (2024)

Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models
by: Jenpei Lee, et al.
Published: (2024)

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
by: Karen Schneck, et al.
Published: (2024)

GLP-1 agonists in treatment of obesity
by: Władysław Orłowski, et al.
Published: (2023)

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
by: Zheng Yang, et al.
Published: (2022)

Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus
by: Julianah Ore Abiola, et al.
Published: (2024)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024)

Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
by: Haran K, et al.
Published: (2024)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
by: Kristina S. Boye, et al.
Published: (2019)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
by: Daiji Kawanami, et al.
Published: (2020)

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
by: Lalita Prasad-Reddy, et al.
Published: (2015)

Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome
by: Marko Ravic, et al.
Published: (2024)

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
by: Ji Hee Yu, et al.
Published: (2022)

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
by: Veronika A. Myasoedova, et al.
Published: (2023)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
by: Cheng D, et al.
Published: (2022)

Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression
by: Stefan Wagner, et al.
Published: (2023)

Baicalein: A potential GLP-1R agonist improves cognitive disorder of diabetes through mitophagy enhancement
by: Na Liu, et al.
Published: (2024)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
by: Antza C, et al.
Published: (2019)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
by: Patrycja Kupnicka, et al.
Published: (2024)

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
by: Joshua J. Neumiller, et al.
Published: (2022)

INITIATING PATIENTS ON GLP-1/COMBINED GLP-1 AND GIP AGONISTS: A QUALITY IMPROVEMENT PROJECT
by: Shreya Srivastava, MD, MPH
Published: (2024)

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis
by: Hui Guo, et al.
Published: (2024)

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
by: Aaron Novikoff, et al.
Published: (2021)

Efficacy and Safety of GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus Treatment: Systematic Review
by: Ana Paula Martins, et al.
Published: (2016)

GLP-1 Receptor: A New Target for Sepsis
by: Fuxun Yang, et al.
Published: (2021)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
by: Wang L
Published: (2022)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
by: Sivasenthil Arumugam, et al.
Published: (2024)

Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus
by: Lora Petrova, et al.
Published: (2024)

GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis
by: Alessandro Mantovani, et al.
Published: (2020)

Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network pharmacology
by: Guorong Deng, et al.
Published: (2023)